|
|
OxyContin Class Action Lawsuits Information
OxyContin reported annual sales exceeding $1 billion in 2000
as Purdue Pharma’s top selling product. The company has been criticized for
using a sales campaign for OxyContin focusing on doctors in order to allow
OxyContin to become a highly financial success without appropriately stressing
the dangers and strength of OxyContin. As a result, some critics believe the
OxyContin sales campaigns caused OxyContin to become one of the most widely
abused narcotic today.
OxyContin maker spent over $500 million according to a Lexington Herald-Leader
report that cited Purdue Pharma corporate records, (8/17/03) to send out a group
of sales reps around the country to introduce OxyContin to family doctors who
were the largest prescribers of competing painkillers. Using highly rewarding
financial incentive for its’ workers, Purdue Pharma used prescribing data about
doctors’ practices to better target potential OxyContin sales. A doctor and
critic of OxyContin has stated that, “when an OxyContin salesman walks in the
door, he knows more about my prescribing than I do,” (AP, 8/18/03).
There are around 285 OxyContin lawsuits still pending against Purdue Pharma. For
more information on OxyContin addiction and OxyContin withdrawal contact us to
confer with an OxyContin lawyer.
OxyContin Side Effects
OxyContin side effects are so dangerous that a former
OxyContin worker from Purdue Pharma claims he was fired over it. The former
employee has filed a lawsuit against the OxyContin makers, claiming his
complaints over OxyContin flaws that could possibly cause OxyContin side effects
resulted in company pressure for him to stay quiet. Purdue has been criticized
for over advertising OxyContin for financial reasons while not emphasizing the
OxyContin side effects if not taken properly.
Due to the dangerous OxyContin side effects, the FFDA has now required that
OxyContin labeling reflect strengthened warnings and precautions. The strongest
FDA warning, called a “black box warning” will now be found on OxyContin
labeling to reduce the risk of OxyContin being prescribed inappropriately and
having OxyContin side effects suffered because of it. Due to the quick
popularity of OxyContin, the drug became the number one prescribed Schedule II
narcotic in the U.S., allowing some critics to believe that OxyContin side
effects were not communicated to patients as well because it became a more
common prescription.
More OxyContin Information
The DEA has stepped in and is trying to increase the amount
of information on OxyContin available to stop OxyContin abuse. Quickly becoming
one of the most abused narcotics, insufficient information on OxyContin was
given to doctors prescribing the powerful drug due to aggressive sales of the
opiate painkillers according to some critics. OxyContin was seen as a
breakthrough in pain management due to the controlled-release dosage form that
could provide up to 12 hours of pain relief, but the information on OxyContin
may not have stressed the dangers of the drug according to some.
Now, after much debate and controversy, the FDA has required that certain
information on OxyContin be changed on the drug’s labeling. The new information
on OxyContin will include the strongest type of FDA warning called a “black box
warning”. The information on OxyContin is intended to reduce the risks of
improper prescribing. One criticism of OxyContin sales is that the company did
not adequately communicate the information on OxyContin stressing that it is
inappropriate for pain not considered for a Schedule II narcotic. OxyContin had
annual sales of over $1 billion in 2000 as it’s best selling product, resulting
from company misuse according to OxyContin opponents.
For more free legal information on known dangerous drugs and Class Action Lawsuits, please use the
links below:
|
